Biotechnology firms develop early-stage therapies and drugs using advanced biological research and innovation. The industry is a segment within the broader healthcare sector.

The industry is driven by R&D pipelines, patent cycles, and regulatory approvals, but risks are high given clinical trial uncertainty and capital intensity.

Dividends are rare in biotech, as most companies prioritize reinvestment and growth. For income investors, exposure is limited, but large, established players may occasionally return cash through dividends or buybacks.

Our biotechnology stocks list includes all NYSE and NASDAQ-listed companies within the biotech industry.